Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5-(3-chlorophenylamino)benzo(c)(2,6)naphthyridine-8-carboxylic Acid
2. Cx 4945
3. Cx-4945
4. Cx4945
1. 1009820-21-6
2. Cx-4945
3. 5-((3-chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic Acid
4. Cx4945
5. Cx 4945
6. Cx-4945 (silmitasertib)
7. Silmitasertib [inn]
8. Cx4945 (silmitasertib)
9. 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid
10. 5-[(3-chlorophenyl)amino]-benzo[c]-2,6-naphthyridine-8-carboxylic Acid
11. Cx-4945 Free Acid
12. C6rwp0n0l2
13. Silmitasertib (cx-4945)
14. Chembl1230165
15. 5-((3-chlorophenyl)amino)benzo-[c][2,6]naphthyridine-8-carboxylic Acid
16. 5-[(3-chlorophenyl)amino]benzo[c]2,6-naphthyridine-8-carboxylic Acid
17. 5-[(3-chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-carboxylic Acid
18. 5-(3-chlorophenylamino)benzo(c)(2,6)naphthyridine-8-carboxylic Acid
19. Unii-c6rwp0n0l2
20. Benzo[c]-2,6-naphthyridine-8-carboxylic Acid, 5-[(3-chlorophenyl)amino]-
21. 5-((3-chlorophenyl)amino)benzo(c)(2,6)naphthyridine-8-carboxylic Acid
22. Benzo(c)-2,6-naphthyridine-8-carboxylic Acid, 5-((3-chlorophenyl)amino)-
23. 3ng
24. 5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic Acid
25. Silmitasertib; Cx 4945
26. Cx-4945 (silmitaserib)
27. Cx 4945 (silmitasertib)
28. Cx-4945 - Silmitasertib
29. Schembl629082
30. Silmitasertib [who-dd]
31. Gtpl8126
32. Dtxsid40143602
33. Ex-a070
34. Hms3244m13
35. Hms3244m14
36. Hms3244n13
37. Hms3655f16
38. Hms3746e13
39. Bcp02399
40. Bdbm50335638
41. Mfcd13184796
42. Nsc761193
43. Nsc800885
44. S2248
45. Zinc58638454
46. 5-[(3-chlorophenyl)amino]benzo[c]-2,6-naphthyridine-8-carboxylic Acid
47. Akos005266722
48. Bcp9000560
49. Ccg-264955
50. Cs-0563
51. Db15408
52. Ex-8673
53. Nsc-761193
54. Nsc-800885
55. Sb17201
56. Ncgc00263192-01
57. Ncgc00263192-02
58. Ncgc00263192-09
59. Ac-28426
60. As-16253
61. Hy-50855
62. Db-016103
63. Ft-0723994
64. Sw218157-2
65. A25034
66. J-000296
67. J-516169
68. W-204393
69. Cx-4945,cas:1009820-21-6
70. Q27076934
71. 5-[(3-chlorophenyl)amino]pyrido[4,3-c]quinoline-8-carboxylic Acid
| Molecular Weight | 349.8 g/mol |
|---|---|
| Molecular Formula | C19H12ClN3O2 |
| XLogP3 | 4.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 3 |
| Exact Mass | 349.0618043 g/mol |
| Monoisotopic Mass | 349.0618043 g/mol |
| Topological Polar Surface Area | 75.1 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 491 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Silmitasertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Silmitasertib, including repackagers and relabelers. The FDA regulates Silmitasertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Silmitasertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Silmitasertib supplier is an individual or a company that provides Silmitasertib active pharmaceutical ingredient (API) or Silmitasertib finished formulations upon request. The Silmitasertib suppliers may include Silmitasertib API manufacturers, exporters, distributors and traders.
Silmitasertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Silmitasertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Silmitasertib GMP manufacturer or Silmitasertib GMP API supplier for your needs.
A Silmitasertib CoA (Certificate of Analysis) is a formal document that attests to Silmitasertib's compliance with Silmitasertib specifications and serves as a tool for batch-level quality control.
Silmitasertib CoA mostly includes findings from lab analyses of a specific batch. For each Silmitasertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Silmitasertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Silmitasertib EP), Silmitasertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Silmitasertib USP).
LOOKING FOR A SUPPLIER?
